Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.
It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction.
The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
The company was incorporated in 2021 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -1.06 Increased by +38.73% | -1.00 Decreased by -6.00% |
| Aug 13, 25 | 0.77 Increased by +174.13% | -1.39 Increased by +155.50% |
| May 14, 25 | -1.82 Increased by +59.56% | -1.42 Decreased by -27.87% |
| Mar 19, 25 | -1.74 | -1.32 Decreased by -31.82% |
| Nov 13, 24 | -1.73 | -1.80 Increased by +4.16% |
| Aug 13, 24 | -1.04 | -1.67 Increased by +37.80% |
| May 29, 24 | -4.50 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 2.07 M Increased by +N/A% | -110.75 M Decreased by -18.94% | Decreased by -5.36 K% Decreased by N/A% |
| Jun 30, 25 | 2.67 M Increased by +N/A% | 59.32 M Increased by +204.98% | Increased by +2.23 K% Decreased by N/A% |
| Mar 31, 25 | 17.39 M Increased by +N/A% | -98.96 M Decreased by -98.53% | Decreased by -569.11% Decreased by N/A% |
| Dec 31, 24 | 3.04 M Increased by +N/A% | -94.76 M Decreased by -141.12% | Decreased by -3.12 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -93.12 M Decreased by -114.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -56.51 M Decreased by -55.72% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -49.85 M Decreased by -38.37% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 - | -39.30 M - | Decreased by N/A% - |